复发高级别胶质瘤再手术联合再放疗的生存获益取决于风险分组
这项回顾性研究分析了2009至2015年间84例复发高级别胶质瘤再手术患者,再手术联合再放疗组中位无进展生存期9.0个月优于单纯再手术组3.5个月(p=0.025),中位总生存期28.1个月对12.7个月(p=0.066)。携带2个及以上风险因素(年龄≥50岁、WHO病理IV级、MGMT启动子未甲基化)的患者获益更明显。再放疗期间4例(8%)出现2级及以上毒性,无放射性坏死。
要点
- 再手术联合再放疗组中位无进展生存期9.0个月,单纯再手术组3.5个月(p=0.025)。
- 中位总生存期再手术联合再放疗组28.1个月,单纯再手术组12.7个月(p=0.066)。
- 携带2个及以上风险因素的患者再放疗在总生存期和无进展生存期上均有获益。
核心结论
- 再手术后行再放疗可耐受,累积中位EQD2为99.3 Gy,在无进展生存期上获益明确,在总生存期上获益有限。
- 再手术联合再放疗的生存获益在携带2个及以上风险因素(年龄≥50岁、WHO病理IV级、MGMT启动子未甲基化)的患者中更突出,该结论需进一步验证。
研究设计与样本
- 回顾性研究分析了2009至2015年间84例接受再手术的复发高级别胶质瘤患者,所有患者复发前均接受过神经外科干预和辅助放疗。
- 复发再手术后治疗方案在多学科门诊或脑肿瘤联合会议上讨论决定,再放疗累积EQD2(α/β=2)低于106.9 Gy。
主要发现
- 中位无进展生存期为6.5个月,单纯再手术组3.5个月,再手术联合再放疗组9.0个月(p=0.025)。
- 中位总生存期为18.3个月,单纯再手术组12.7个月,再手术联合再放疗组28.1个月(p=0.066)。
- 多因素分析中,年龄<50岁、复发间隔≥12个月、WHO病理III级、MGMT启动子甲基化和再放疗是延长无进展生存期的因素。
- 多因素分析中,年龄>50岁、WHO病理IV级和MGMT启动子未甲基化与较差的总生存期显著相关。
- 再放疗期间4例(8%)出现2级及以上毒性,3例(6%)未完成再放疗,未观察到放射性坏死。
关键数值与推荐
- 再放疗累积EQD2(α/β=2)低于106.9 Gy,累积中位EQD2为99.3 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 再手术联合再放疗的生存获益在携带2个及以上风险因素的患者中更突出,该结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A majority of high-grade gliomas relapse despite combined surgery, radiotherapy and chemotherapy. There is no consensus on standard treatment for recurrent high-grade gliomas, or defined efficacy of adjuvant re-RT after re-Op. This retrospective study evaluated the benefit and safety of re-RT after re-Op (re-Op/RT). MATERIALS AND METHODS: A total of 84 patients with recurrent high-grade gliomas who underwent reoperation from 2009 to 2015 were analyzed. All patients received neurosurgical intervention and adjuvant radiotherapy previously before recurrence. At recurrence and after reoperation, treatment options were discussed in multidisciplinary clinic or brain tumor joint conference. For re-RT, cumulative EQD2 (equivalent dose in 2 Gy fractions at α/β = 2) was below 106.9 Gy. RESULT: Median progression free survival (PFS) was 6.5 months; 3.5 months with re-Op, 9.0 months with re-Op/RT (p = 0.025). Age <50, time interval to recur ≥12 months, WHO pathologic grade III, methylated MGMT promotor, and re-RT were factors enhancing PFS in the multivariate analysis. Median overall survival (OS) was 18.3 months: 12.7 months with re-Op, and 28.1 months with re-Op/RT (p = 0.066). Three risk factors (age >50, WHO grade IV, and unmethylated promoter of MGMT) were significantly associated with poor OS in multivariate analysis. Benefit of re-RT in both OS and PFS was established in patients carrying 2 or more risk factors. During re-RT, 4 patients (8%) had grade 2 or higher toxicity, and 3 patients (6%) did not complete re-RT. No radionecrosis was observed. CONCLUSION: Re-RT after re-Op was tolerable with a cumulative median EQD2 of 99.3 Gy and resulted in clear benefit in PFS and marginal gain in OS. Survival gain with re-Op/RT was more prominent in patients with two or more risk factors (age ≥50, WHO pathologic grade IV, unmethylated MGMT promoter), and needs to be validated.
引用
- Chun SJ, Park SH, Park CK, et al. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups. Radiother Oncol. 2018. PMID: 29937212. doi:10.1016/j.radonc.2018.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。